<SEC-DOCUMENT>0001193125-23-271422.txt : 20231106
<SEC-HEADER>0001193125-23-271422.hdr.sgml : 20231106
<ACCEPTANCE-DATETIME>20231106164256
ACCESSION NUMBER:		0001193125-23-271422
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231106
FILED AS OF DATE:		20231106
DATE AS OF CHANGE:		20231106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231380500

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d440070d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as November 6, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d440070dex991.htm">Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III
 Trial in Metastatic Breast Cancer </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 6, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d440070dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g440070g32b99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Completion of the Safety <FONT STYLE="white-space:nowrap">Lead-In</FONT> and Opening of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Randomized Phase II of the <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Phase II/III Trial in Metastatic Breast Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No safety or tolerability issues in open-label, safety <FONT STYLE="white-space:nowrap">lead-in</FONT> phase
evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Good safety profile allows for <FONT STYLE="white-space:nowrap">lead-in</FONT> phase to be closed early and
the randomized Phase II portion of study will now proceed</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 06 November </B><B>2023 &#150;</B> <U>Immutep
Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today
announces the open-label safety <FONT STYLE="white-space:nowrap">lead-in</FONT> of its integrated <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Phase II/III trial evaluating for the very first time 90mg of eftilagimod alpha (efti) in combination
with paclitaxel has been completed with no safety or tolerability issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Six patients with metastatic breast cancer receiving this immuno-oncology
chemotherapy <FONT STYLE="white-space:nowrap">(IO-chemo)</FONT> combination, after exhaustion of all endocrine/CDK4/6 based therapies, tolerated the therapy very well and there were no dose limiting toxicities, as confirmed by the independent Data
Monitoring Committee (IDMC) appointed for the trial. The IDMC recommended proceeding to the randomised Phase II portion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The randomised
(1:1) Phase II portion of the study will now open to include up to 58 evaluable patients with metastatic breast cancer receiving either 30mg efti or 90mg efti to determine the optimal biological dose. The evaluation of 90mg efti dosing in
combination with paclitaxel is driven by efti&#146;s excellent safety profile, along with the <U>FDA&#146;s Project Optimus</U> initiative in oncology. Importantly the determination of the optimal biological dose is relevant for the whole efti
program across all disease indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <U>integrated Phase II/III <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial</U> is evaluating efti,
Immutep&#146;s soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> paclitaxel for the treatment of metastatic hormone receptor positive (HR+),&nbsp;HER2-negative&nbsp;or <FONT STYLE="white-space:nowrap">HER2-low</FONT> breast
cancer and triple-negative breast cancer. It will take place at approximately 17 clinical sites across Europe and the United States of America. For more information on the trial, please visit clinicaltrials.gov (<U>NCT05747794</U>). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further
boost the immune system&#146;s ability to fight cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g440070g32b99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell
lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti has received Fast
Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the CEO of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George
Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g440070g32b99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g440070g32b99.jpg
M_]C_X08'17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4
M    G0$[  (    )    L8=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P(#(T+C4@*%=I;F1O=W,I #(P,C,Z,3$Z,#8@
M,#DZ-#8Z,C$ <G(T,34P,S0      Z !  ,    !__\  * "  0    !   #
M-* #  0    !    :@         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M_P!7_P""3EPNA>[5R,FSJ]C*<-UF-8QKWUBV6!XW>B,NIV.]_J?9;&_T>_\
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M_P#)I1UK][&_S;/_ ":^8DDO\97_ (8_3L=:_>QO\VS_ ,FE'6OWL;_-L_\
M)KYB22_QE?\ AC].QUK][&_S;/\ R:4=:_>QO\VS_P FOF))+_&5_P"&/T['
M6OWL;_-L_P#)I1UK][&_S;/_ ":^8DDO\97_ (8_3L=:_>QO\VS_ ,FE'6OW
ML;_-L_\ )KYB22_QE?X[_]G_[0ZB4&AO=&]S:&]P(#,N,  X0DE-! 0
M &$< 5H  QLE1QP"   "   < E  "')R-#$U,#,T' (% $!-:6-R;W-O9G0@
M5V]R9" M($-O;7!L971I;VX@;V8@4V%F971Y($QE860M26X@9F]R($%)4$%#
M+3 P,U\V3F]V #A"24T$)0      $)&@-VNA*L2,;,-MICY0G_\X0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ $L     0 ! 2P    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$1       $     (   )    "0      X0DE-!!X       0
M.$))300:      .E    !@              :@   S0    X $, ;P!M '
M; !E '0 :0!O &X ( !O &8 ( !3 &$ 9@!E '0 >0 @ $P 90!A &0 +0!)
M &X ( !F &\ <@ @ $$ 20!0 $$ 0P M #  ,  S %\ -@!. &\ =@ R #,
M1@!) $X 00!, "T ,0    $                          0
M   #-    &H                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   &H     4F=H=&QO;F<   ,T    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   !J     %)G
M:'1L;VYG   #-     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M ":^8DDO\97_ (8_3L=:_>QO\VS_ ,FE'6OWL;_-L_\ )KYB22_QE?X[_]D
M.$))300A      !7     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #(
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M Q$ /P#OX
M
M              ?#^!&?3KT+\"_;_H 13<G/N21]=Y79Z\TC0T&;W5!)?KLI
MS*^DSE8I47$=:F95'3P:Q<:5DMA7NI-,IY,EB(PZDVB4ZM*THB&K\TTY6[<R
MFGVHN7J9PJJF?LTS'3&$;:ICZIPB=DN+<X?-JUI&<OZ5R]EK>9S=J9BY<KFK
M[JBJ)PFB(IPFNJGX_:BF)V8SMPP9@'W#>6KM]B,>STW0[+A9R4Z9BU!BU#>X
MYD.5UE2^XS<2<.L/S.\KY2:MQE:'7),<F&U)_P"T=07[PUN5YGU:;MFFK(TW
MHN8X4T1--<X=,TXS,3$?6CFF?-/GBK-9"G,<O49NUF8FJU1;HKHN7::9PKJM
M3UJJ9IIPG&:HPB8VS'2F"U/M?$]R8A&S#$GIB&"ES*>\I+B$]5Y)B.3U3A,7
MF)953223*I\AI))_+?96711&EQM2VEMK5-\GG+.>LQ>L8X8S$Q.R::HZ::H^
M$Q_+8[KHFM9'7\A;S^1KJZF,TUT51--RU<IV5VKM$[:+E$[*J9^J8QIF)G)8
MRFW     '__0[^
M
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MB;L5Q3UL(V1C35U<(V84TQ\$X@G[T6     /_]'OX
M
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MOORPY-S?+V5SFK:O1%&KYS#['QM6XF:HHG#[,5UU3-=<1LIV4X_9E(V)0ZL
M    /__2[^
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MN>F*HB8G\,3L4>BP/!L6D.2\9PS%,<E.H-MV318[3U$AU!_BAQZOAQW%H/\
ML,S(6[>7R]JKK6K%%-7TQ3$3_-#%RVFZ?DZIKR>0LVJIZ9HHIIF>S$+K%YF@
M      __T^_@
M                                               &@/W,/Z4\B_C+
M7?\ -< 1WFK]S7O[]'YT.9?-W^"<W^T6/]2EBS[4/_*'9W^:3G\IX^,#D_\
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M^V5EEQF7!3CI:7LR3864##9>*KFRW%O/R(>&9%=8G4J4ZX:EN=BIIF$=3/\
MV0&]X        #__U._@
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M_]7OX
M                                        !C_9NK<$W'B<G!]CT+>2
M8O+FUUA(JW9EA 0Y,J9;<ZO>.15RX4M)QY325$1.$D^G0R,O@,;-Y3+YZS5E
M\U;Z]F9B<,9C;$XQT3$]+6:OHVFZ]DJ].U;*Q>R555-4TS-4;:9BJF<:9B=D
MQCTJ1J;2.L-&U%I0ZLQ=G%:BZM3N[.&S86UBF5:'$CP3E&[;S[!YLSBQ6T=E
M"DH_=Z].O4Q1DLAE-/MU6LG9BBB:L9VS.W##';,_"%C1.7M'Y<L7<KHN3BQE
MZZ^O53$U58U81&.-4U3CA$1TX;.AC^FX?\=L?V(SM>GUU&A[ CY'99:SD)7N
M3.NHR"W5-58V'T3]R[6J5)58O&:#9^67;_=270NF+1H>F6LU^N6\K$9GK35U
ML:NF>F<,</C+66.1>5<MJT:Y8TFFG5?OJKOWG7N3/7KQZU6$U]7;UIV881\(
MAFW-\*QK8V)7^#9E6IN<6RBN>J;VJ6_*BHGUTCI\^,J1!?C2V2<))?O-N(47
M[#&POV+69LW+%ZGK6JXPF/IA(<_D,IJF2S.G9^S%S)WJ)IKIG&(JIGIC&)B=
MTPQWJ/CGIO1,J^EZJPUC$W\F9KF+Q;-K>67U[=4J6NO2HKBSL$L_3JFN_P#=
MDDU=OX]>A=,7):7D=.FY.3L=2:\,=LSCAT=,S],M5H7*G+_+569KT33HL5WH
MIBN8JKJZT4X]7^O55T8ST8=+V;<T'J?>T>AA[6Q-G+(N,3)EA1LO65Q6E!F6
M$9,.6\E5/85ZWC>C))/1PU)3^)$1_$59W3<EJ,6Z<Y8BN*)F8VS&$SL^$PN:
MYRUHG,E&6MZWD(OT6:IJHB:JJ>K,QA,XTU4SMC9MV+@P[5F"X#KZ+JS$J)NH
MP2% LZN+0HF6$IMJON7IDBRCE-FRI%BHI3U@\HU&Z:D]O]TR(BZ7;&3R^6RM
M.3L6^KEHIF(C;LB>G;.WXSTLK(Z/IVFZ9;T?)9:*--HHJIBC&J8ZM4S-48S,
MU;>M/QQ8YU1Q1T#H_(7,JU=K^-BM\[2O8\Y/9NLCL#53R)$24[#^3;W$^,1+
MD06E=HD=O]SIUZ&?7$R>C:;D+OWV4RT47.K,8XU3LGX;9GZ&IT3DKEGEW-59
MS1M+IL9B:.IC%=<_9F8F8PJJJCIB-S(&T]1Z\W5C",-V;CK648VW;0+M%8].
MLZ]!6E9\WZ&5\^IFP)1J8-]71/;[!]?B1_ 96<R65S]F+&;M=>UUHG#&8VQT
M=$Q+9ZSH>E<PY.-/UC*1>R?7BOJS-41UJ<<)QIFF=F,[,<'\M5:>UUI+')&(
MZPQQK%L<E7$V_D5K4ZSL$N7%@U%CRYGS[:;/E)4\U":2:262"[/P(NI]63R6
M5T^S-C*6NI:FJ9PQF=L]/3,R^:+H.E<NY2K(Z-E(L92;DUS3$U58U581,XU3
M5.W"/C@L?;7%;0V]+Z+DNU,"CY7=0J/].19KUUD5<;--]5*F?1$S46]?'47U
M,QU?;-!N?O=.UT(B+&SNCZ=J%RF[G,M%=R*<,<9C9]&R8^F6NUSDSEGF3,T9
MO6M,B_F*;7W<3-5=.%&,U884U4QTS,XX8_6SI454&CJ:RDJV"BUE/7PZNMC)
M6XX4:!7QFXD..3CJUNN$S'92GM*4:CZ=3,S&PMT4VZ*+=,84TQ$1]41T)'8L
MV\M9M9>S3A9MTQ33'T4TQ$1'XHCXM+][?;GXB\B,CG9KGVKFH.<6JVW+C,L'
MO+K!K^\<:2;:';U[')L*'=RB1T3\^6R]([*23V^R1$*UUA_'OL\\%:.6F5,U
M]E^5I29&<+*]H9W85Z^G7X.Q(EW7MNI/]I*ZD?[0&_VK=3:VTGA=;KO4^&TF
M!X34.SI%?CF/QCBU\>19RW9]C)[*EN..R9TU];KKBU*6XM1F9F9@, <A>!O%
MSD];HR?:VM8\K-6X4:M+.\9MKC#\P>KXG4HL*QN<>FP7+J-%0?991-3))E/[
MK?9+X ,:ZB^UOPSTQE]%GN.Z[N+[+L5N(&0XM<YQFV594K'+RL>)^!:U,";9
MIJF9\1XB4VZMA:D*+J1D8#?VTJJN\K9U-=UL"XJ+2(_ LZJTB1["ML8,IM3,
MF%/@RVWHLR)(96:5MN(4A:3,C(R,!&QFGVA>#&86KUM%UM>X(Y(<<>?KM=9U
ME.*T2G77%..+8H&;"145Z5*5_P!W%99:27P)) ,BZ8^VGPZT5E%!G6&:N<L,
MYQ:>=IC>7YEE.49?<45A\AZ+]95(N+5^K@RRCR'$DZW'2XDEF1*^(".[[\__
M  SQ8_CC9?\ *52 N#AC]NCB;R3X::!V'L?7LUG/KK'+IR^S'$,KR3$+F_5"
MS+):^*N[_)K)B!9O,0HC;2776%/=A!%V^A$0"2?C]P3XN<9+161ZHU?7P<R7
M$=@*SK(K"TR_,VX3Y&A^)"O\CF6,JHC2&U&EU$/Z=+R?@X2B ;=_@
M   /_];OX
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M+[6?] G'#^&<D_G_ "T!(            #__U^_@
M
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MA-!KC6>+U6%X+B\>1$Q[&*1E4>KJ8TJ;*LI#,-E2W%(0].FNNG\3_?<,!>X
M          /_T._@
M
M                                !__1[^
M
M                                                       '_]+O
MX
M
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MKOGGW!G>Q3X1[NN6_K-M+P*N\I!QO6O,+NZ.Z>N^>?<&=[%/A'NZY;^LVTO
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M@#>=P!O.X WG< ;SN -YW &\[@#>=P!O.X WG< ;SN -YW &\[@#>=P!O.X
MWG< ;SN -YW &\[@#>=P!O.X WG< ;SN -YW &\[@#>=P!O.X WG< ;SN -Y
MW &\[@#>=P!O.X WG< ;SN -YW &\[@#>=P!O.X WG< ;SN -YW &\[@#>=P
M!O.X WG< ;SN -YW &\[@#>=P!O.X WG< ;SN -YW &\[@#>=P!O.X WG< ;
=WY_V_P#U'^K_ -/[_P#T"KX?R_E@?R^O_P"'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
